[go: up one dir, main page]

MX2019015065A - Metodo para tratamiento de trombocitopenia inmunitaria. - Google Patents

Metodo para tratamiento de trombocitopenia inmunitaria.

Info

Publication number
MX2019015065A
MX2019015065A MX2019015065A MX2019015065A MX2019015065A MX 2019015065 A MX2019015065 A MX 2019015065A MX 2019015065 A MX2019015065 A MX 2019015065A MX 2019015065 A MX2019015065 A MX 2019015065A MX 2019015065 A MX2019015065 A MX 2019015065A
Authority
MX
Mexico
Prior art keywords
treatment
human
immune thrombocytopenia
range
treatment period
Prior art date
Application number
MX2019015065A
Other languages
English (en)
Inventor
Rocio Lledo-Garcia
Grant Langdon
Claus Peter Kiessling
Rose Gunter Snipes
Ute Massow
Original Assignee
UCB Biopharma SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1709554.8A external-priority patent/GB201709554D0/en
Priority claimed from GBGB1718589.3A external-priority patent/GB201718589D0/en
Application filed by UCB Biopharma SRL filed Critical UCB Biopharma SRL
Publication of MX2019015065A publication Critical patent/MX2019015065A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/624—Disulfide-stabilized antibody (dsFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La descripción se refiere a un método para tratar o prevenir la púrpura trombocitopénica (idiopática) inmune (ITP) en un ser humano que lo necesite, el método que comprende administrar al ser humano en el intervalo de 1 a 5 dosis de un anticuerpo de anti-FcRn o fragmento de unión al antígeno del mismo durante un período de tratamiento de 1 a 12 semanas, en donde la dosis agregada en el período de tratamiento está en el intervalo de 1 a 30 mg por kg.
MX2019015065A 2017-06-15 2018-06-15 Metodo para tratamiento de trombocitopenia inmunitaria. MX2019015065A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1709554.8A GB201709554D0 (en) 2017-06-15 2017-06-15 Method of treatment
GBGB1718589.3A GB201718589D0 (en) 2017-11-10 2017-11-10 Method of treatment
PCT/EP2018/065947 WO2018229249A1 (en) 2017-06-15 2018-06-15 Method for the treatment of immune thrombocytopenia

Publications (1)

Publication Number Publication Date
MX2019015065A true MX2019015065A (es) 2020-08-03

Family

ID=62684788

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019015065A MX2019015065A (es) 2017-06-15 2018-06-15 Metodo para tratamiento de trombocitopenia inmunitaria.

Country Status (16)

Country Link
US (1) US20200140548A1 (es)
EP (1) EP3638305A1 (es)
JP (1) JP2020523419A (es)
KR (1) KR20200018643A (es)
CN (1) CN110785186A (es)
AU (1) AU2018285577A1 (es)
BR (1) BR112019026694A2 (es)
CA (1) CA3066298A1 (es)
CL (1) CL2019003673A1 (es)
CO (1) CO2019014525A2 (es)
IL (1) IL271248A (es)
MA (1) MA49378A (es)
MX (1) MX2019015065A (es)
RU (1) RU2020100880A (es)
SG (1) SG11201911832PA (es)
WO (1) WO2018229249A1 (es)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009524664A (ja) * 2006-01-25 2009-07-02 ザ リサーチ ファウンデイション オブ ステイト ユニバーシティー オブ ニューヨーク 自己／アロ免疫疾患の治療のための抗−ｆｃｒｎ抗体
BRPI0910622A2 (pt) * 2008-04-25 2020-03-10 Dyax Corp. ANTICORPOS CONTRA FcRn E USOS DOS MESMOS
BR112013030352B1 (pt) * 2011-06-02 2020-05-19 Dyax Corp. anticorpo anti-fcrn isolado, composição farmacêutica que compreende o dito anticorpo, ácido nucleico isolado, vetor, célula e uso terapêutico do dito anticorpo
GB201208370D0 (en) * 2012-05-14 2012-06-27 Ucb Pharma Sa Antibodies
ES2952583T3 (es) * 2014-04-30 2023-11-02 Hanall Biopharma Co Ltd Anticuerpo de unión a FcRn para tratar enfermedades autoinmunes
CN118667015A (zh) * 2015-01-30 2024-09-20 动量制药公司 Fcrn抗体及其使用方法
GB201508180D0 (en) * 2015-05-13 2015-06-24 Ucb Biopharma Sprl Antibodies

Also Published As

Publication number Publication date
CA3066298A1 (en) 2018-12-20
WO2018229249A1 (en) 2018-12-20
SG11201911832PA (en) 2020-01-30
KR20200018643A (ko) 2020-02-19
RU2020100880A3 (es) 2021-11-10
EP3638305A1 (en) 2020-04-22
US20200140548A1 (en) 2020-05-07
CO2019014525A2 (es) 2020-04-24
BR112019026694A2 (pt) 2020-06-23
RU2020100880A (ru) 2021-07-15
CN110785186A (zh) 2020-02-11
CL2019003673A1 (es) 2020-07-17
IL271248A (en) 2020-01-30
MA49378A (fr) 2020-04-22
JP2020523419A (ja) 2020-08-06
AU2018285577A1 (en) 2020-01-30

Similar Documents

Publication Publication Date Title
PH12019501706A1 (en) A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease
MY208022A (en) Anti-claudin 18.2 antibody and application thereof
JO3559B1 (ar) جسم مضاد لعلاج أو الوقاية من الصداع النصفي وطريقة استخدامه
EA201690905A1 (ru) Специфические антитела против cd38 для лечения злокачественных новообразований у человека
MX2020002750A (es) Anticuerpo il-6r y fragmento de union a antigeno y uso medico.
AU2018290532A1 (en) Immunotherapy for hepatocellular carcinoma
MY202368A (en) Methods of treating ulcerative colitis
MX2023004314A (es) Anticuerpos ligando anti grupo de diferenciacion 40 (cd40) terapeuticos.
PH12021550226A1 (en) A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease
MX368228B (es) Anticuerpos que se unen específicamente a her2.
EA036102B9 (ru) Терапевтические средства с углевод-опосредованной адресной доставкой
MX2017005642A (es) Anticuerpos anti-angiopoyetina 2 (ang2) y metodos de uso.
EP4276108A3 (en) Methods of treatment of diseases in which il-13 activity is detrimental using anti-il-13 antibodies
MX2019001958A (es) Metodos para tratar la enfermedad de crohn con un anticuerpo anti-nkg2d.
MX2021004351A (es) Metodo para el tratamiento de miastenia grave.
MY201301A (en) Glucagon receptor binding proteins and methods of use thereof
PH12016500677A1 (en) Specific anti-cd38 antibodies for treating human cancers
MX2017001176A (es) Terapia de combinacion.
EP4252847A3 (en) Regimens and methods of treating multiple sclerosis using ofatumumab
PH12017502126A1 (en) Novel anti-human ngf antibody fab fragment
MX2020007050A (es) Una combinacion de inmunoglobulina plasmatica e inmunoglobulina especifica de antigeno para la modificacion del sistema inmune y el tratamiento o prevencion de enfermedades alergicas.
ZA202108094B (en) Mirikizumab for use in a method of treating crohn's disease
MX2019015065A (es) Metodo para tratamiento de trombocitopenia inmunitaria.
WO2020086479A9 (en) Dosing
MX2020005438A (es) Formas de dosificacion de sulfato de morfina disuasivas del abuso.